2024-514520-16-00招募中1 期
A Randomized, Double-Blind, Placebo Controlled, Multi - Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis
Liveome Inc.3 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2024年11月18日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 8
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Sophie Hyun-Ja Ko
Scientific
Liveome Inc.
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
1 期
A clinical study to compare the effect of Ibrutinib or placebo on prolongation of event free survival in patients with early stage Binet A CLL with a high risk for disease progression defined by various clincial and laboratory risk factors.Patients with Chronic Lymphocytic Leukemia Binet A stage.EUCTR2013-003211-22-DEniversity of Cologne540
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures. - ELEVATEEUCTR2007-005851-40-BEGlaxoSmithKline Research and Development Ltd500
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)Resected Squamous Cell Carcinoma of the Head and NeckMedDRA version: 8.1Level: LLTClassification code 10041823Term: Squamous cell carcinomaEUCTR2006-001623-18-LVGlaxoSmithKline Research & Development Limited680
进行中（未招募）
1 期
Phase II Study to evaluate Olaparib with Abiraterone in treating metastatic castration resistant prostate cancermetastatic castrate-resistant prostate cancerMedDRA version: 18.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003520-37-CZAstraZeneca AB170
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)EUCTR2006-001623-18-EEGlaxoSmithKline Research & Development Limited680